NCT04919811: An ongoing trial by Nuvation Bio, Inc.
This trial is ongoing. It must report results 1 week ago.
Full data
| Full entry on ClinicalTrials.gov | NCT04919811 |
|---|---|
| Title | A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 1, 2021 |
| Completion date | June 11, 2025 |
| Required reporting date | June 11, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |